Disease progression, drug action and Parkinson’s disease: Why time cannot be ignored
- First Online:
- Cite this article as:
- Holford, N. & Nutt, J.G. Eur J Clin Pharmacol (2008) 64: 207. doi:10.1007/s00228-007-0427-9
- 107 Downloads
Slope of linear disease status curve
Effect compartment concentration
Steady state effect site concentration at the start of each levodopa infusion derived from endogenous dopamine and previous exogenous levodopa administration
Non-steady state levodopa concentration in plasma
Non-steady state component of the slow equilibration effect compartment
Maximum levodopa induced response above baseline
Duration of uniform diurnal input.
Concentration at which 50% of maximum response is produced.
Maximum tapping rates that a drug can produce.
Hill coefficient which determine the steepness of the concentration–response curve.
Ratio of diurnal input to constant input of endogenous dopamine
Rate of levodopa equivalent dopamine synthesis in the dopa synthesis effect compartment during the diurnal input period
Equilibration half-life of the dopa synthesis effect compartment
Equilibration half-life of the fast equilibration effect compartment
Equilibration half-life of the slow equilibration effect compartment